Latest Insider Transactions at Celldex Therapeutics, Inc. (CLDX)
This section provides a real-time view of insider transactions for Celldex Therapeutics, Inc. (CLDX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Celldex Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Celldex Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 08
2021
|
Sarah Cavanaugh SVP OF CORP AFFAIRS & ADMIN. |
BUY
Exercise of conversion of derivative security
|
Direct |
7,323
+43.23%
|
$65,907
$9.7 P/Share
|
Nov 15
2021
|
Samuel Bates Martin SVP AND CFO |
SELL
Open market or private sale
|
Direct |
9,500
-13.78%
|
$408,500
$43.09 P/Share
|
Nov 15
2021
|
Samuel Bates Martin SVP AND CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+9.2%
|
$35,000
$5.9 P/Share
|
Nov 12
2021
|
Diane C. Young SVP, CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,600
-68.5%
|
$193,200
$42.94 P/Share
|
Nov 12
2021
|
Diane C. Young SVP, CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,600
+40.65%
|
$46,000
$10.38 P/Share
|
Nov 01
2021
|
Margo Heath Chiozzi SVP OF REGULATORY AFFAIRS |
SELL
Open market or private sale
|
Direct |
600
-5.06%
|
$24,600
$41.71 P/Share
|
Nov 01
2021
|
Margo Heath Chiozzi SVP OF REGULATORY AFFAIRS |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+4.82%
|
$1,200
$2.78 P/Share
|
Nov 01
2021
|
Elizabeth Crowley SR. VP & CPDO |
SELL
Open market or private sale
|
Direct |
4,317
-19.09%
|
$181,314
$42.95 P/Share
|
Nov 01
2021
|
Elizabeth Crowley SR. VP & CPDO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,555
+48.61%
|
$17,110
$2.78 P/Share
|
Nov 01
2021
|
Sarah Cavanaugh SVP OF CORP AFFAIRS & ADMIN. |
SELL
Open market or private sale
|
Direct |
7,323
-55.26%
|
$307,566
$42.93 P/Share
|
Nov 01
2021
|
Sarah Cavanaugh SVP OF CORP AFFAIRS & ADMIN. |
BUY
Exercise of conversion of derivative security
|
Direct |
5,956
+26.65%
|
$29,780
$5.9 P/Share
|
Aug 11
2021
|
Freddy A. Jimenez SVP & GENERAL COUNSEL |
BUY
Open market or private purchase
|
Direct |
430
+50.0%
|
$19,780
$46.28 P/Share
|
Aug 11
2021
|
Margo Heath Chiozzi SVP OF REGULATORY AFFAIRS |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+47.07%
|
$90,000
$9.02 P/Share
|
Aug 10
2021
|
Samuel Bates Martin SVP AND CFO |
SELL
Open market or private sale
|
Direct |
2,738
-6.02%
|
$123,210
$45.25 P/Share
|
Aug 10
2021
|
Samuel Bates Martin SVP AND CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,381
+29.9%
|
$106,905
$5.9 P/Share
|
Aug 05
2021
|
Anthony S Marucci PRESIDENT & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,537
+11.5%
|
$148,554
$42.0 P/Share
|
Dec 14
2020
|
Richard M. Wright SR. VP & CCO |
SELL
Open market or private sale
|
Direct |
20,832
-98.02%
|
$374,976
$18.61 P/Share
|
Dec 14
2020
|
Richard M. Wright SR. VP & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,832
+49.5%
|
$104,160
$5.9 P/Share
|